Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

Martha Wadleigh, Paul G. Richardson, David Zahrieh, Stephanie J. Lee, Corey Cutler, Vincent Ho, Edwin P. Alyea, Joseph H. Antin, Richard M. Stone, Robert J. Soiffer, Daniel J. DeAngelo

Research output: Contribution to journalArticle

219 Citations (Scopus)

Abstract

Gemtuzumab ozogamicin (GO), a monoclonal antibody used in the treatment of acute myelogenous leukemia (AML) has been linked to the development of venoocclusive disease (VOD). We conducted a retrospective study of 62 patients with previously treated AML/MDS (myelodysplastic syndrome) who underwent allogeneic stem cell (SC) transplantation at our institution from December 2000 to October 2002 to determine whether GO exposure prior to allogeneic SC transplantation increases the risk of developing VOD. Fourteen patients received GO prior to SC transplantation. Of 62 patients, 13 (21%) developed VOD; 9 (64%) of 14 with prior GO exposure developed VOD compared with 4 (8%) of 48 without prior GO exposure (P < .0001). Logistic regression controlling for sex, disease status, donor type, and graft-versus-host disease prophylaxis identified prior treatment with GO as a significant risk factor for VOD (odds ratio [OR], 21.6; 95% confidence interval [CI], 4.2-112.2]. Nine of 10 patients who underwent SC transplantation 3.5 months or less following GO developed VOD compared with none of 4 patients who underwent SC transplantation more than 3.5 months from GO administration. Three of 14 patients who received GO prior to SC transplantation died of VOD. We conclude that patients undergoing SC transplantation within a short interval from GO administration are at increased risk of developing VOD.

Original languageEnglish (US)
Pages (from-to)1578-1582
Number of pages5
JournalBlood
Volume102
Issue number5
DOIs
StatePublished - Sep 1 2003
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Stem cells
Acute Myeloid Leukemia
gemtuzumab
Myelodysplastic Syndromes
Graft vs Host Disease
Grafts
Logistics
Retrospective Studies
Logistic Models
Odds Ratio
Monoclonal Antibodies
Tissue Donors
Confidence Intervals

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. / Wadleigh, Martha; Richardson, Paul G.; Zahrieh, David; Lee, Stephanie J.; Cutler, Corey; Ho, Vincent; Alyea, Edwin P.; Antin, Joseph H.; Stone, Richard M.; Soiffer, Robert J.; DeAngelo, Daniel J.

In: Blood, Vol. 102, No. 5, 01.09.2003, p. 1578-1582.

Research output: Contribution to journalArticle

Wadleigh, M, Richardson, PG, Zahrieh, D, Lee, SJ, Cutler, C, Ho, V, Alyea, EP, Antin, JH, Stone, RM, Soiffer, RJ & DeAngelo, DJ 2003, 'Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation', Blood, vol. 102, no. 5, pp. 1578-1582. https://doi.org/10.1182/blood-2003-01-0255
Wadleigh, Martha ; Richardson, Paul G. ; Zahrieh, David ; Lee, Stephanie J. ; Cutler, Corey ; Ho, Vincent ; Alyea, Edwin P. ; Antin, Joseph H. ; Stone, Richard M. ; Soiffer, Robert J. ; DeAngelo, Daniel J. / Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. In: Blood. 2003 ; Vol. 102, No. 5. pp. 1578-1582.
@article{6f21c911623c469db3e13d1172d44dab,
title = "Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation",
abstract = "Gemtuzumab ozogamicin (GO), a monoclonal antibody used in the treatment of acute myelogenous leukemia (AML) has been linked to the development of venoocclusive disease (VOD). We conducted a retrospective study of 62 patients with previously treated AML/MDS (myelodysplastic syndrome) who underwent allogeneic stem cell (SC) transplantation at our institution from December 2000 to October 2002 to determine whether GO exposure prior to allogeneic SC transplantation increases the risk of developing VOD. Fourteen patients received GO prior to SC transplantation. Of 62 patients, 13 (21{\%}) developed VOD; 9 (64{\%}) of 14 with prior GO exposure developed VOD compared with 4 (8{\%}) of 48 without prior GO exposure (P < .0001). Logistic regression controlling for sex, disease status, donor type, and graft-versus-host disease prophylaxis identified prior treatment with GO as a significant risk factor for VOD (odds ratio [OR], 21.6; 95{\%} confidence interval [CI], 4.2-112.2]. Nine of 10 patients who underwent SC transplantation 3.5 months or less following GO developed VOD compared with none of 4 patients who underwent SC transplantation more than 3.5 months from GO administration. Three of 14 patients who received GO prior to SC transplantation died of VOD. We conclude that patients undergoing SC transplantation within a short interval from GO administration are at increased risk of developing VOD.",
author = "Martha Wadleigh and Richardson, {Paul G.} and David Zahrieh and Lee, {Stephanie J.} and Corey Cutler and Vincent Ho and Alyea, {Edwin P.} and Antin, {Joseph H.} and Stone, {Richard M.} and Soiffer, {Robert J.} and DeAngelo, {Daniel J.}",
year = "2003",
month = "9",
day = "1",
doi = "10.1182/blood-2003-01-0255",
language = "English (US)",
volume = "102",
pages = "1578--1582",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

AU - Wadleigh, Martha

AU - Richardson, Paul G.

AU - Zahrieh, David

AU - Lee, Stephanie J.

AU - Cutler, Corey

AU - Ho, Vincent

AU - Alyea, Edwin P.

AU - Antin, Joseph H.

AU - Stone, Richard M.

AU - Soiffer, Robert J.

AU - DeAngelo, Daniel J.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Gemtuzumab ozogamicin (GO), a monoclonal antibody used in the treatment of acute myelogenous leukemia (AML) has been linked to the development of venoocclusive disease (VOD). We conducted a retrospective study of 62 patients with previously treated AML/MDS (myelodysplastic syndrome) who underwent allogeneic stem cell (SC) transplantation at our institution from December 2000 to October 2002 to determine whether GO exposure prior to allogeneic SC transplantation increases the risk of developing VOD. Fourteen patients received GO prior to SC transplantation. Of 62 patients, 13 (21%) developed VOD; 9 (64%) of 14 with prior GO exposure developed VOD compared with 4 (8%) of 48 without prior GO exposure (P < .0001). Logistic regression controlling for sex, disease status, donor type, and graft-versus-host disease prophylaxis identified prior treatment with GO as a significant risk factor for VOD (odds ratio [OR], 21.6; 95% confidence interval [CI], 4.2-112.2]. Nine of 10 patients who underwent SC transplantation 3.5 months or less following GO developed VOD compared with none of 4 patients who underwent SC transplantation more than 3.5 months from GO administration. Three of 14 patients who received GO prior to SC transplantation died of VOD. We conclude that patients undergoing SC transplantation within a short interval from GO administration are at increased risk of developing VOD.

AB - Gemtuzumab ozogamicin (GO), a monoclonal antibody used in the treatment of acute myelogenous leukemia (AML) has been linked to the development of venoocclusive disease (VOD). We conducted a retrospective study of 62 patients with previously treated AML/MDS (myelodysplastic syndrome) who underwent allogeneic stem cell (SC) transplantation at our institution from December 2000 to October 2002 to determine whether GO exposure prior to allogeneic SC transplantation increases the risk of developing VOD. Fourteen patients received GO prior to SC transplantation. Of 62 patients, 13 (21%) developed VOD; 9 (64%) of 14 with prior GO exposure developed VOD compared with 4 (8%) of 48 without prior GO exposure (P < .0001). Logistic regression controlling for sex, disease status, donor type, and graft-versus-host disease prophylaxis identified prior treatment with GO as a significant risk factor for VOD (odds ratio [OR], 21.6; 95% confidence interval [CI], 4.2-112.2]. Nine of 10 patients who underwent SC transplantation 3.5 months or less following GO developed VOD compared with none of 4 patients who underwent SC transplantation more than 3.5 months from GO administration. Three of 14 patients who received GO prior to SC transplantation died of VOD. We conclude that patients undergoing SC transplantation within a short interval from GO administration are at increased risk of developing VOD.

UR - http://www.scopus.com/inward/record.url?scp=0042442407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042442407&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-01-0255

DO - 10.1182/blood-2003-01-0255

M3 - Article

C2 - 12738663

AN - SCOPUS:0042442407

VL - 102

SP - 1578

EP - 1582

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -